

Rachel Smith, PA-S

Evidence Based Practice

Arcadia University

July 17, 2020

The efficacy and safety of novel immunotherapy agent in high-grade urothelial carcinoma

## References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *European Urology*. 2017;71(1):96-108. doi:10.1016/j.eururo.2016.06.010.
2. Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. *Cancer Treatment Reviews*. 2017;54:58-67. doi:10.1016/j.ctrv.2017.01.007
3. Clark PE, Agarwal N, Biagioli MC, et al. Bladder Cancer. *Journal of the National Comprehensive Cancer Network*. 2013;11(4):446-475. doi:10.6004/jnccn.2013.0059.
4. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. *Journal of Clinical Oncology*. 2011;29(17):2432-2438. doi:10.1200/jco.2011.34.8433.
5. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *European Urology*. 2013;63(2):234-241. doi:10.1016/j.eururo.2012.07.033.
6. Gorelov AI, Simbirtsev AS, Zhuravskii DA, Gorelova AA. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. *Urologic Oncology: Seminars and Original Investigations*. 2017;35(1):14-20. doi:10.1016/j.urolonc.2016.10.004.
7. ECOG Performance Status. ECOG-ACRIN. <https://ecog-acrin.org/resources/ecog-performance-status>. Accessed April 6, 2020.
8. Balar AV, Castellano D, Odonnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer

(KEYNOTE-052): a multicentre, single-arm, phase 2 study. *The Lancet Oncology*. 2017;18(11):1483-1492. doi:10.1016/s1470-2045(17)30616-2.

9. Powles T, Durán I, Heijden MSVD, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *The Lancet*. 2018;391(10122):748-757. doi:10.1016/s0140-6736(17)33297-x.
10. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *The Lancet Oncology*. 2018;19(1):51-64. doi:10.1016/s1470-2045(17)30900-2.
11. Bellmunt J, Wit RD, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *New England Journal of Medicine*. 2017;376(11):1015-1026. doi:10.1056/nejmoa1613683.
12. Powles T, Odonnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. *JAMA Oncology*. 2017;3(9). doi:10.1001/jamaoncol.2017.2411.
13. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *The Lancet*. 2017;389(10064):67-76. doi:10.1016/s0140-6736(16)32455-2.
14. Patterson K, Prabhu V, Xu R, et al. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. *European Urology Oncology*. 2019;2(5):565-571. doi:10.1016/j.euo.2018.09.009.